Applying Evidence and Expert Experience to Optimize Management and Overcome Challenges in CLL

Join us for this live, 1-hour ACPE-certified webinar, as Lydia Benitez, PharmD, BCOP, and Caitlin Rausch, PharmD, highlight optimal pharmacist treatment selection and management approaches for patients with CLL/SLL.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

1:30–1:35 PM Welcome and Program Overview

1:35- 2:00 PM Current Treatment Pathways and Regimen Comparisons in CLL/SLL

2:00-2:20 PM Role of Pharmacists in Optimizing CLL Management, and Emerging Strategies

2:20-2:30 PM Audience Q&A and Closing Remarks

Events

Date / Time
Event Details

Faculty

Faculty
Lydia Benitez, PharmD, BCOP

Clinical Assistant Professor
Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Outpatient Leukemia Pharmacy Specialist
Department of Pharmacy
Michigan Medicine
Ann Arbor, Michigan

Faculty
Caitlin R. Rausch, PharmD

Clinical Pharmacy Specialist, Leukemia
Division of Pharmacy
University of Texas MD Anderson Cancer Center
Houston, Texas

Program Overview
This program presents the latest clinical data to aid pharmacists in providing optimal care for their patients with CLL/SLL, including downloadable slides with PracticePoints based on presentations from a live, 1-hour webinar, and a ClinicalThought commentary with key take-home points and FAQs from the webinar.

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of pharmacists in the management of patients with CLL/SLL.

Target Audience
The target audience for this activity is pharmacists, including clinical, managed care, and specialty pharmacists, who care for patients with CLL as well as other stakeholders in hematology/oncology practice.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Devise treatment plans for treatment-naive and relapsed/refractory CLL/SLL, including consideration of the agent’s toxicity profile, biomarkers, comorbidities, and patient preference
  • Evaluate intraclass differences for agents with similar therapeutic targets in CLL/SLL, regarding selectivity, target binding, efficacy, and adverse event profiles
  • Plan strategies by which hematology-oncology pharmacists can optimize outcomes for patients with CLL/SLL, including addressing adverse event management, medication adherence, and minimizing potential drug–drug interactions
  • Examine the evolving role of measurable residual disease, fixed duration treatment plans, and CAR T-cell therapy in CLL/SLL care

Accreditation

CE Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-162-L01-P has been assigned to this live knowledge-based activity (initial release date 5/18/2022). This activity is approved for 1.0 contact hour (0.10 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.